|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2003-2-14
|
|
pubmed:abstractText |
To determine maximum-tolerated dose, toxicities, and pharmacokinetics associated with weekly intravesical gemcitabine therapy in patients with superficial bladder cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
21
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
697-703
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12586808-Administration, Intravesical,
pubmed-meshheading:12586808-Aged,
pubmed-meshheading:12586808-Aged, 80 and over,
pubmed-meshheading:12586808-Antimetabolites, Antineoplastic,
pubmed-meshheading:12586808-Carcinoma, Transitional Cell,
pubmed-meshheading:12586808-Chromatography, High Pressure Liquid,
pubmed-meshheading:12586808-Deoxycytidine,
pubmed-meshheading:12586808-Female,
pubmed-meshheading:12586808-Humans,
pubmed-meshheading:12586808-Male,
pubmed-meshheading:12586808-Middle Aged,
pubmed-meshheading:12586808-Urinary Bladder Neoplasms
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study.
|
|
pubmed:affiliation |
Department of Urology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
